Korolev D.V.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Korolev D.V. has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Natal'YA Gennad'EVna Plekhova
Pacific State Medical University
2 shared publications - Валентин Борисович Шуматов
Pacific State Medical University, Vladivostok, Russian Federation
2 shared publications Bystritskaya A.S.
Pacific State Medical University, 690002, Vladivostok, Russia
1 shared publicationLisitsa G.T.
Pacific State Medical University, 690002, Vladivostok, Russia
1 shared publicationVoroshilov A.D.
Pacific State Medical University, 690002, Vladivostok, Russia
1 shared publication
Latest Publications
- 30 July 2023
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
LOCAL TREATMENT OF INFECTED WOUNDS DEPENDING ON THE PHASE OF THE WOUND PROCESS
Despite the availability of a large number of funds for the treatment of infected wounds, this issue of clinical medicine does not lose its relevance. In most cases, a combined method of wound treatment is used, which implies both the use of systemic drugs and local treatment, which, taking into account the phase of the wound process, should be aimed at cleansing, reducing inflammation, stimulating regeneration. At the present stage of the development of medicine, dressings used in surgery should meet the principle of wound healing in a humid environment and have certain requirements: to restrain the ingress of microorganisms into the wound, the composition of dressings should not include components that have toxic, allergic, mutagenic and carcinogenic effects. Recently, considerable progress has been made in the development of new methods of treating infected wounds, which are based on the impact of chemical and physical factors on the healing process, taking into account a personalized approach to the patient, based primarily on his general condition and the ability of the body to resist infection. The review, based on modern literature data, presents a generalized analysis of the use of dosage forms and wound coatings in various phases of the wound process, with an emphasis on phase I as the most aggressive for the macroorganism. The criterion for evaluating the correct treatment is to reduce the time of wound healing and prevent the development of complications. An important modern criterion for the effectiveness of wound healing is the aesthetic appearance of the scar, which encourages the search for new ways to treat wounds, a combination of already known drugs and the continuation of research in the field of wound coatings.
- 30 July 2023
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
LOCAL TREATMENT OF INFECTED WOUNDS DEPENDING ON THE PHASE OF THE WOUND PROCESS
Despite the availability of a large number of funds for the treatment of infected wounds, this issue of clinical medicine does not lose its relevance. In most cases, a combined method of wound treatment is used, which implies both the use of systemic drugs and local treatment, which, taking into account the phase of the wound process, should be aimed at cleansing, reducing inflammation, stimulating regeneration. At the present stage of the development of medicine, dressings used in surgery should meet the principle of wound healing in a humid environment and have certain requirements: to restrain the ingress of microorganisms into the wound, the composition of dressings should not include components that have toxic, allergic, mutagenic and carcinogenic effects. Recently, considerable progress has been made in the development of new methods of treating infected wounds, which are based on the impact of chemical and physical factors on the healing process, taking into account a personalized approach to the patient, based primarily on his general condition and the ability of the body to resist infection. The review, based on modern literature data, presents a generalized analysis of the use of dosage forms and wound coatings in various phases of the wound process, with an emphasis on phase I as the most aggressive for the macroorganism. The criterion for evaluating the correct treatment is to reduce the time of wound healing and prevent the development of complications. An important modern criterion for the effectiveness of wound healing is the aesthetic appearance of the scar, which encourages the search for new ways to treat wounds, a combination of already known drugs and the continuation of research in the field of wound coatings.
- 30 April 2023
- Published by Technomed Holdings LLC in Bulletin "Biomedicine and sociology"
STUDY OF ACUTE AND CHRONIC TOXICITY A DRUG FOR PHARMACO-CORRECTION OF LIVER FIBROSIS
The article presents data on the study on laboratory animals of the parameters acute and chronic toxicity a drug for pharmacocorrection of liver fibrosis - collagenase from crab hepatopancreas (collagenase CH). In a comparative study, the activity of collagenase CH significantly exceeded that of proteinases isolated from St. lavendulae and the indicators were 4.02±0.02 U/mg and 3.6±0.03 U/mg (p<0.01), respectively. A single intraperitoneal injection of the drug at a dose of 5000 mg/kg into non-linear mice caused their death within 1 day as a type of drug-induced anaphylactic shock. In the liver, circulatory hypoxia developed, up to necrosis, a sharp congestion of large vessels, plasma impregnation of their walls, aggregation and stasis in the vessels of the microvasculature, up to fibrinoid necrosis. Injection of collagenase CH in doses from 4000 mg/kg to 100 mg/kg body weight was tolerated without visible consequences throughout the entire observed period (30 days). Taking into account such data, this drug is classified as low-toxic and, according to GOST 12.1.007-76 “Harmful substances”, belongs to hazard class 4 (low-hazard substances). It has been established that collagenase CH in doses close to therapeutic (400, 200, 100 μg/kg) does not cause pronounced disturbances in liver architecture, manifested by the development of necrotic and dystrophic changes in the parenchyma. When studying chronic toxicity, the drug at the indicated concentrations does not have a toxic effect on the liver, which suggests its use for the development of new complex drugs for the treatment of fibrosis and other pathologies associated with connective tissue.
- 30 April 2023
- Published by Technomed Holdings LLC in Bulletin "Biomedicine and sociology"
STUDY OF ACUTE AND CHRONIC TOXICITY A DRUG FOR PHARMACO-CORRECTION OF LIVER FIBROSIS
The article presents data on the study on laboratory animals of the parameters acute and chronic toxicity a drug for pharmacocorrection of liver fibrosis - collagenase from crab hepatopancreas (collagenase CH). In a comparative study, the activity of collagenase CH significantly exceeded that of proteinases isolated from St. lavendulae and the indicators were 4.02±0.02 U/mg and 3.6±0.03 U/mg (p<0.01), respectively. A single intraperitoneal injection of the drug at a dose of 5000 mg/kg into non-linear mice caused their death within 1 day as a type of drug-induced anaphylactic shock. In the liver, circulatory hypoxia developed, up to necrosis, a sharp congestion of large vessels, plasma impregnation of their walls, aggregation and stasis in the vessels of the microvasculature, up to fibrinoid necrosis. Injection of collagenase CH in doses from 4000 mg/kg to 100 mg/kg body weight was tolerated without visible consequences throughout the entire observed period (30 days). Taking into account such data, this drug is classified as low-toxic and, according to GOST 12.1.007-76 “Harmful substances”, belongs to hazard class 4 (low-hazard substances). It has been established that collagenase CH in doses close to therapeutic (400, 200, 100 μg/kg) does not cause pronounced disturbances in liver architecture, manifested by the development of necrotic and dystrophic changes in the parenchyma. When studying chronic toxicity, the drug at the indicated concentrations does not have a toxic effect on the liver, which suggests its use for the development of new complex drugs for the treatment of fibrosis and other pathologies associated with connective tissue.